TW200833356A - Prophylactic and/or therapeutic agent for fatty liver - Google Patents

Prophylactic and/or therapeutic agent for fatty liver

Info

Publication number
TW200833356A
TW200833356A TW096134632A TW96134632A TW200833356A TW 200833356 A TW200833356 A TW 200833356A TW 096134632 A TW096134632 A TW 096134632A TW 96134632 A TW96134632 A TW 96134632A TW 200833356 A TW200833356 A TW 200833356A
Authority
TW
Taiwan
Prior art keywords
fatty liver
prophylactic
therapeutic agent
prevent
diabetes
Prior art date
Application number
TW096134632A
Other languages
Chinese (zh)
Inventor
Kazuwa Nakao
Hiroshi Itoh
Kazutoshi Miyashita
Takuhiro Sonoyama
Naohisa Tamura
Original Assignee
Daiichi Sankyo Co Ltd
Univ Kyoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd, Univ Kyoto filed Critical Daiichi Sankyo Co Ltd
Publication of TW200833356A publication Critical patent/TW200833356A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Disclosed is a prophylactic and/or therapeutic agent for fatty liver, which comprises an agonist against a natriuretic peptide receptor GC-A. The pharmaceutical agent can prevent or treat fatty liver, and can also prevent metabolic syndrome including obesity and diabetes.
TW096134632A 2006-09-15 2007-09-14 Prophylactic and/or therapeutic agent for fatty liver TW200833356A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006250529 2006-09-15

Publications (1)

Publication Number Publication Date
TW200833356A true TW200833356A (en) 2008-08-16

Family

ID=39183519

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096134632A TW200833356A (en) 2006-09-15 2007-09-14 Prophylactic and/or therapeutic agent for fatty liver

Country Status (3)

Country Link
JP (1) JPWO2008032450A1 (en)
TW (1) TW200833356A (en)
WO (1) WO2008032450A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120208756A1 (en) 2009-07-23 2012-08-16 Igisu Co., Ltd Composition for external preparation for skin
RU2502519C2 (en) 2009-08-27 2013-12-27 Кёко ЭНДО Therapeutic agent for treating rhinitis
BR112013018679B1 (en) 2011-01-21 2022-04-12 Igisu Co. Ltd. Agent for the treatment of alopecia and use of a c-type natriuretic peptide
WO2016131943A1 (en) * 2015-02-20 2016-08-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of obesity and complications arising therefrom including type 2 diabetes
US20180066020A1 (en) 2015-05-29 2018-03-08 Igisu Co., Ltd. A cyclic peptide and a medicament, external preparation and cosmetic comprising said cyclic peptide

Also Published As

Publication number Publication date
WO2008032450A1 (en) 2008-03-20
JPWO2008032450A1 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
IL219915A0 (en) Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
TN2012000216A1 (en) Pharmaceutical composition comprising a glp-1 agonist, an insulin, and methionine
WO2006097536A3 (en) Dimeric peptide agonists of the glp-1 receptor
IL202269A0 (en) Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
WO2010043566A3 (en) Combination of an insulin and a glp-1 agonist
WO2007028633A3 (en) Treatment of diabetes related obesity
WO2007100535A3 (en) Oxyntomodulin derivatives
WO2011069038A3 (en) Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2322620A3 (en) Analogs of human pancreatic polypeptide and their effects on feeding behaviour
TW200731968A (en) Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or H3 receptor antagonist/inverse agonist
PT2040755E (en) Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity
TW200833356A (en) Prophylactic and/or therapeutic agent for fatty liver
WO2007144732A3 (en) Inter-subsystem transfers
EP1898849A4 (en) New regimens for controlled drug delivery devices for contraception
IL188668A0 (en) Daily dosage regimen for treating diabetes, obesity, metabolic syndrome and polycystic ovary syndrome
EP1938810A4 (en) Ameliorating agent for metabolic syndrome
WO2011092473A8 (en) Novel compounds and their effects on feeding behaviour
WO2008008348A3 (en) Method and compositions for treating stroke with fever
EP1982724A4 (en) Therapeutic agent for metabolic syndrome and food containing the therapeutic agent
EP2502996A3 (en) Anti-FGF23 antibody and pharmaceutical composition comprising the same
UA88655C2 (en) S-mirtazapine for the treatment of hot flush
SI2101730T1 (en) Galenic form for the transmucosal delivery of paracetamol
WO2008079727A3 (en) Compositions comprising an pan-alpha-2 receptor agonist and an anticonvulsant for treating chronic pain
WO2007130507A3 (en) Acute pain medications based on fast acting diclofenac-opioid combinations
WO2007141743A3 (en) A tablet dosage form comprising cetirizine and pseudoephedrine